The ingredient name is the beginning of a medication description. It is not the entire identity of the product. A provider page can discuss semaglutide research and offer a compounded preparation on the same screen. The reader still needs to distinguish the evidence for a studied product from the product that will actually be dispensed.
FDA-approved drugs go through an approval process for the particular product. Compounded medicines do not receive that same premarket FDA review of safety, effectiveness and quality. The FDA also distinguishes compounding from approved generics: a compounded preparation is not an FDA-approved generic equivalent simply because it contains the same named ingredient. [Regulator guidance]
What compounding is intended to address
Compounding can serve a patient whose needs cannot be met by an available approved medicine. FDA's patient information gives examples such as an allergy to a dye or the need for a different dosage form. The rules and circumstances matter; the presence of a compounded offer online does not establish that it is appropriate for every patient who wants a lower price. [Regulator guidance]
For GLP-1 medicines specifically, the FDA advises people to obtain a prescription and use a state-licensed pharmacy. Its current concerns page says compounded treatment should be used when a patient's medical needs cannot be met by an approved drug. Discuss that question with the prescriber instead of treating a marketing description as a clinical justification. [Regulator guidance]
What a research result can and cannot establish
A trial of an approved product can tell readers about the participants, product and conditions actually studied. It does not automatically measure the outcomes of a telehealth service or every compounded formulation containing that ingredient. A provider's use of a trial percentage is not evidence that its own customers achieved that result.
Read claims in layers: the medicine studied, the people studied, the amount of time followed and the care delivered alongside the medicine. NIDDK describes weight-management medication as part of a broader treatment approach. A result from a study should not become a personal promise or a reason to choose a higher dose without clinical guidance. [Federal patient education]
Why the label and the pharmacy matter
FDA has reported dosing errors with compounded injectable semaglutide, including confusion among milligrams, milliliters and syringe markings. Different concentrations and packaging can make copying someone else's instructions dangerous. Ask the dispensing pharmacist to explain the dose for your actual prescription, container and syringe. This article deliberately provides no conversion table or dosing schedule. [Safety alert, July 2024]
The agency has also warned about fraudulent product labels and semaglutide salt forms that differ from the ingredient in approved drugs. Knowing the dispensing pharmacy's name and having a way to contact it are practical parts of understanding a prescription. “Made in a licensed pharmacy” and “FDA-approved product” answer different questions. [Regulator guidance]
Questions that belong in the consultation
- What exact medication, formulation and dosage form are you considering for me?
- Is the product FDA-approved or compounded?
- If compounded, why is an available approved option unable to meet my medical needs?
- Which pharmacy will dispense it, and how can I verify its state license?
- Who will explain administration and handle changes in concentration or packaging?
A careful provider should be able to discuss the proposed treatment without treating these questions as an obstacle. Read our online-provider checklist for the care and communication questions that sit beside medication identity. You can also compare the clearly labeled treatment categories in our six-option guide.
Sources & evidence notes
Public pages checked October 5, 2026. Provider pages establish what a company advertises; they do not independently verify its performance.
- FDA — concerns with unapproved GLP-1 drugsRegulator guidance
- FDA — compounding questions and answersRegulator guidance
- FDA — dosing errors with compounded injectable semaglutideSafety alert, July 2024
- NIDDK — prescription medications for overweight and obesityFederal patient education